Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.
Garrett N, Reddy T, Yende-Zuma N, Takalani A, Woeber K, Bodenstein A, Jonas P, Engelbrecht I, Jassat W, Moultrie H, Bradshaw D, Seocharan I, Odhiambo J, Khuto K, Richardson SI, Omondi MA, Nesamari R, Keeton RS, Riou C, Moyo-Gwete T, Innes C, Zwane Z, Mngadi K, Brumskine W, Naicker N, Potloane D, Badal-Faesen S, Innes S, Barnabas S, Lombaard J, Gill K, Nchabeleng M, Snyman E, Petrick F, Spooner E, Naidoo L, Kalonji D, Naicker V, Singh N, Maboa R, Mda P, Malan D, Nana A, Malahleha M, Kotze P, Allagappen JJ, Diacon AH, Kruger GM, Patel F, Moore PL, Burgers WA, Anteyi K, Leav B, Bekker LG, Gray GE, Goga A; SHERPA study team. Garrett N, et al. Among authors: riou c. PLOS Glob Public Health. 2024 Dec 5;4(12):e0003260. doi: 10.1371/journal.pgph.0003260. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39636838 Free PMC article.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Le Roux J, Lustig G, Madzivhandila M, Magugu SFJ, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L. Riou C, et al. PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38603677 Free PMC article.
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
Keeton R, Richardson SI, Moyo-Gwete T, Hermanus T, Tincho MB, Benede N, Manamela NP, Baguma R, Makhado Z, Ngomti A, Motlou T, Mennen M, Chinhoyi L, Skelem S, Maboreke H, Doolabh D, Iranzadeh A, Otter AD, Brooks T, Noursadeghi M, Moon JC, Grifoni A, Weiskopf D, Sette A, Blackburn J, Hsiao NY, Williamson C, Riou C, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Moore PL, Burgers WA. Keeton R, et al. Among authors: riou c. Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5. doi: 10.1016/j.chom.2021.10.003. Epub 2021 Oct 13. Cell Host Microbe. 2021. PMID: 34688376 Free PMC article.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL. Moyo-Gwete T, et al. Among authors: riou c. medRxiv [Preprint]. 2023 Mar 15:2023.03.15.23287288. doi: 10.1101/2023.03.15.23287288. medRxiv. 2023. Update in: PLoS Pathog. 2023 Nov 9;19(11):e1011772. doi: 10.1371/journal.ppat.1011772 PMID: 36993404 Free PMC article. Updated. Preprint.
Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells.
Krause RGE, Moyo-Gwete T, Richardson SI, Makhado Z, Manamela NP, Hermanus T, Mkhize NN, Keeton R, Benede N, Mennen M, Skelem S, Karim F, Khan K, Riou C, Ntusi NAB, Goga A, Gray G, Hanekom W, Garrett N, Bekker LG, Groll A, Sigal A, Moore PL, Burgers WA, Leslie A. Krause RGE, et al. Among authors: riou c. NPJ Vaccines. 2023 Aug 12;8(1):119. doi: 10.1038/s41541-023-00724-9. NPJ Vaccines. 2023. PMID: 37573434 Free PMC article.
The immune response to SARS-CoV-2 in people with HIV.
Höft MA, Burgers WA, Riou C. Höft MA, et al. Among authors: riou c. Cell Mol Immunol. 2024 Feb;21(2):184-196. doi: 10.1038/s41423-023-01087-w. Epub 2023 Oct 11. Cell Mol Immunol. 2024. PMID: 37821620 Free PMC article. Review.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, Ayres F, Makhado Z, Motlou T, Tincho MB, Benede N, Ngomti A, Baguma R, Chauke MV, Mennen M, Adriaanse M, Skelem S, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Riou C, Burgers WA, Moore PL. Moyo-Gwete T, et al. Among authors: riou c. PLoS Pathog. 2023 Nov 9;19(11):e1011772. doi: 10.1371/journal.ppat.1011772. eCollection 2023 Nov. PLoS Pathog. 2023. PMID: 37943890 Free PMC article.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Roux JL, Lustig G, Madzivhandila M, Magugu SF, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L. Riou C, et al. medRxiv [Preprint]. 2023 Nov 20:2023.11.20.23298785. doi: 10.1101/2023.11.20.23298785. medRxiv. 2023. Update in: PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703 PMID: 38045321 Free PMC article. Updated. Preprint.
T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, Khan K, Cele S, Bernstein M, Karim F, Madzorera SV, Moyo-Gwete T, Mennen M, Skelem S, Adriaanse M, Mutithu D, Aremu O, Stek C, du Bruyn E, Van Der Mescht MA, de Beer Z, de Villiers TR, Bodenstein A, van den Berg G, Mendes A, Strydom A, Venter M, Giandhari J, Naidoo Y, Pillay S, Tegally H, Grifoni A, Weiskopf D, Sette A, Wilkinson RJ, de Oliveira T, Bekker LG, Gray G, Ueckermann V, Rossouw T, Boswell MT, Bhiman JN, Moore PL, Sigal A, Ntusi NAB, Burgers WA, Riou C. Keeton R, et al. Among authors: riou c. Nature. 2022 Mar;603(7901):488-492. doi: 10.1038/s41586-022-04460-3. Epub 2022 Jan 31. Nature. 2022. PMID: 35102311 Free PMC article.
139 results